DCMIC
OMIC

Decheng Capital Management III (Cayman)’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-667
Closed -$76K – 28
2022
Q2 		$76K Hold
667
– – 0.03% 25
2022
Q1 		$126K Buy
+667
New +$154K 0.04% 24

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s OMIC Position: Q3 2022 in Review

Decheng Capital Management III (Cayman) sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q3 2022, closing a stake of 667 shares — an estimated $76K sold.

Decheng Capital Management III (Cayman) first reported a position in OMIC in Q1 2022 and held it in 2 quarters. The position peaked at $126K in Q1 2022. 74 funds tracked by Wall St. Rank hold OMIC as of Q3 2022.

  • Decheng Capital Management III (Cayman) reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Decheng Capital Management III (Cayman) sold 667 Singular Genomics Systems, Inc. Common Stock shares in Q3 2022, an estimated $76K.
  • Decheng Capital Management III (Cayman) first reported a position in Singular Genomics Systems, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Decheng Capital Management III (Cayman)'s Singular Genomics Systems, Inc. Common Stock position peaked at $126K in Q1 2022.
  • 74 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q3 2022.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2022, filed 8 Nov 2022.